ReviewWorld journal of gastroenterology2007
Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?
Review in World journal of gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 37 citations in OpenAlex.
- Matrix Stiffness and Biochemistry Govern Colorectal Cancer Cell Growth and Signaling in User-Programmable Synthetic Hydrogels.ACS biomaterials science & engineering · 2025Article
- The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics.Leukemia research reports · 2022Article
- Design and Production of Bispecific Antibodies.Antibodies (Basel, Switzerland) · 2019Review
- Expression of p53 & epidermal growth factor receptor in glioblastoma.The Indian journal of medical research · 2017Article
- Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer.BMC cancer · 2014Article
- TNF-α converting enzyme-mediated ErbB4 transactivation by TNF promotes colonic epithelial cell survival.American journal of physiology. Gastrointestinal and liver physiology · 2011Article
- Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells.Molecular cancer · 2011Article
- Epidermal growth factor receptor mutations in colorectal cancer patients.Journal of the Korean Society of Coloproctology · 2011Article
- Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium.The Journal of clinical investigation · 2009Article
- Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice.Gastroenterology · 2009Article
- Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer.Nature reviews. Gastroenterology & hepatology · 2009Review
- Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim.Biomedical imaging and intervention journal · 2008Article
- Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor.Therapeutic advances in gastroenterology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer constitutes one of the most common malignancies and the second leading cause of death from cancer in the western world representing one million new cases and half a million deaths annually worldwide. The treatment of patients with metastatic colon cancer comprises different regimens of chemotherapeutic compounds (fluoropyrimidines, irinotecan and oxaliplatin) and new targeted therapies. Interestingly, most recent trials that attempt to expose patients to all five-drug classes (fluoropyrimidines, irinotecan, oxaliplatin, bevacizumab and cetuximab) achieve an overall survival well over 2 years. In this review we will focus on the main epidermal growth factor receptor inhibitors demonstrating clinical benefit for colorectal cancer mainly cetuximab, panitumumab, erlotinib and gefitinib. We will also describe briefly the molecular steps that lie beneath them and the different clinical or molecular mechanisms that are reported for resistance and response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.